| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/BMM.13.12 |
| P698 | PubMed publication ID | 23547822 |
| P50 | author | Matthias Preusser | Q18001566 |
| P2093 | author name string | Ludwig Wagner | |
| Aysegül Ilhan-Mutlu | |||
| P2860 | cites work | Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas | Q49072695 |
| Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort | Q49093554 | ||
| Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. | Q49118867 | ||
| Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. | Q52409953 | ||
| Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. | Q53602150 | ||
| Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. | Q54499903 | ||
| Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels. | Q55462867 | ||
| Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. | Q55467627 | ||
| YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. | Q55469339 | ||
| Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. | Q55476209 | ||
| IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee | Q58003101 | ||
| MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators | Q24336898 | ||
| RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls | Q24594189 | ||
| Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 | ||
| Plasma netrin-1 is a diagnostic biomarker of human cancers | Q24629347 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages | Q28114942 | ||
| Serum YKL-40 following resection for cerebral glioblastoma | Q28253544 | ||
| S100beta as a predictor of brain metastases: brain versus cerebrovascular damage | Q48841414 | ||
| Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors | Q48852873 | ||
| Cathepsin D is a potential serum marker for poor prognosis in glioma patients | Q48852906 | ||
| Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor | Q48922428 | ||
| Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients | Q48934243 | ||
| PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value | Q48951220 | ||
| MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells | Q28262214 | ||
| Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy | Q28279046 | ||
| miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors | Q28307352 | ||
| Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis | Q28484143 | ||
| Prediction of central nervous system embryonal tumour outcome based on gene expression | Q29618619 | ||
| Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions | Q30432850 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| Identification of prognostic factors in patients with brain metastases: a review of 1292 patients | Q33177750 | ||
| Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors | Q33193164 | ||
| Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer | Q33252970 | ||
| Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology | Q33282542 | ||
| Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma | Q33320144 | ||
| Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide | Q33391770 | ||
| Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis | Q33433688 | ||
| Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma | Q33481160 | ||
| Biomarkers for serum diagnosis of infectious diseases and their potential application in novel sensor platforms. | Q33549902 | ||
| Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). | Q33923906 | ||
| Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma | Q33990834 | ||
| The functional and clinical roles of osteopontin in cancer and metastasis. | Q34119050 | ||
| Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades | Q34132740 | ||
| Elevated blood markers 1 year before manifestation of malignant glioma | Q34133105 | ||
| Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas | Q34279430 | ||
| Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor | Q34480501 | ||
| Identification of diagnostic serum protein profiles of glioblastoma patients | Q34981475 | ||
| Monoclonal antibody specific for IDH1 R132H mutation | Q35006135 | ||
| Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas | Q35419401 | ||
| Early postoperative serum S100 beta levels predict ongoing brain damage after meningioma surgery: a prospective observational study | Q35544698 | ||
| Alexander disease: putative mechanisms of an astrocytic encephalopathy | Q35652990 | ||
| Insulin-like growth factor binding protein 2 promotes glioma development and progression | Q35880328 | ||
| Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. | Q35974626 | ||
| Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke | Q36142617 | ||
| Association between prediagnostic IgE levels and risk of glioma | Q36179217 | ||
| Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 | ||
| Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors | Q36622856 | ||
| Breast cancer screening and biomarkers | Q37358047 | ||
| Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas | Q37395331 | ||
| Early diagnosis of acute kidney injury: the promise of novel biomarkers | Q37546577 | ||
| Therapy and prophylaxis of brain metastases | Q37809862 | ||
| Brain metastases: pathobiology and emerging targeted therapies. | Q37972783 | ||
| CSF and laboratory analysis (tumor markers). | Q37974360 | ||
| Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. | Q38290930 | ||
| G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer | Q38409117 | ||
| Circulating microRNAs as novel minimally invasive biomarkers for breast cancer | Q39281588 | ||
| Exploratory investigation of eight circulating plasma markers in brain tumor patients | Q39319659 | ||
| S100B protein as a possible participant in the brain metastasis of NSCLC. | Q39404676 | ||
| Proteomic Identification of Haptoglobin α2 as a Glioblastoma Serum Biomarker: Implications in Cancer Cell Migration and Tumor Growth | Q39658758 | ||
| Circulating microRNAs in plasma of patients with gastric cancers | Q39986294 | ||
| Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia | Q40005850 | ||
| Detection of IDH1 mutation in the plasma of patients with glioma | Q40066837 | ||
| Serum GFAP is a diagnostic marker for glioblastoma multiforme | Q40155072 | ||
| CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome | Q42479350 | ||
| Allergies and adult gliomas: cohort results strengthen evidence for a causal association | Q42954516 | ||
| Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations | Q42957960 | ||
| CXCL13 and CXCL12 in central nervous system lymphoma patients. | Q43272851 | ||
| Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer | Q43857101 | ||
| Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma | Q43995413 | ||
| Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens | Q44649106 | ||
| Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma | Q45094676 | ||
| Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors | Q45101245 | ||
| Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction | Q45167064 | ||
| A specific miRNA signature in the peripheral blood of glioblastoma patients | Q45256953 | ||
| Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. | Q45953731 | ||
| The alteration of plasma TGF-β1 levels in patients with brain tumors after tumor removal | Q46109838 | ||
| Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy | Q46542581 | ||
| 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size | Q47355822 | ||
| Low-molecular weight caldesmon as a potential serum marker for glioma | Q47378237 | ||
| Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers | Q47770190 | ||
| Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme | Q47914088 | ||
| Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis | Q48173788 | ||
| Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. | Q48250421 | ||
| Blood alterations preceding clinical manifestation of glioblastoma | Q48338469 | ||
| Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients | Q48409555 | ||
| Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma | Q48462130 | ||
| Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors | Q48551502 | ||
| G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker | Q48579799 | ||
| Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma | Q48584168 | ||
| Decrease in circulating endothelial progenitor cells in treated glioma patients. | Q48651060 | ||
| Neurospecific proteins in the serum of patients with brain tumors | Q48717903 | ||
| p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas | Q48728141 | ||
| P433 | issue | 2 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 267-285 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Biomarkers in Medicine | Q20313333 |
| P1476 | title | Circulating biomarkers of CNS tumors: an update | |
| P478 | volume | 7 |
| Q30358150 | Advances in diagnostic and treatment modalities for intracranial tumors. |
| Q38591062 | Emerging circulating biomarkers in glioblastoma: promises and challenges. |
| Q37639524 | Evaluation of matrix metalloproteinase type IV-collagenases in serum of patients with tumors of the central nervous system |
| Q28081953 | Gliomas and the vascular fragility of the blood brain barrier |
| Q52679143 | How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology. |
| Q38365590 | Liquid biopsies in patients with diffuse glioma |
| Q87480876 | MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: a Meta-analysis |
| Q27009190 | Molecular biology of high-grade gliomas: what should the clinician know? |
| Q48467746 | Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma |
| Q41122605 | S100 B: A new concept in neurocritical care |
| Q55460538 | Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis. |
| Q37225239 | The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients |
| Q38239173 | Towards developing biomarkers for glioblastoma multiforme: a proteomics view |
Search more.